ClinicalTrials.gg
RecruitingNCT05946642BF-IPTscUpdated Nov 22, 2023

Innovative Intermittent Preventive Treatment Approaches to Reduce Malaria Burden in School-age Children in Burkina Faso

A Phase 3 interventional study of Sulphadoxine-Pyrimethamine/Amodiaquine and Dihydroartemisinin/Piperaquine (DP) plus Ivermectin (IVM) in Malaria, sponsored by Malaria Consortium. Recruiting at 1 site in Burkina Faso. Open to participants aged 5 Years to 15 Years. Per ClinicalTrials.gov, last updated 2023-11-22.

Sponsored by Malaria Consortium · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by May 2024, 2 years 5 months ago, but the record still lists the study as recruiting.
  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
13,000
Allocation
Randomized
Ages
5 Years to 15 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies testing amodiaquine in Malaria — 2 open to participants now, 5 under way, 2 of them phase 3. Amodiaquine · Malaria.

Planned enrollment
4th of 44
13,000 · median 738
Started
2023
the only one that year
Phase 3
16 of 46
1 open now
Registered
44th of 46
by date
Lead sponsor
4 of 46
Malaria Consortium

Among the 46 studies testing amodiaquine in Malaria, this one is the 4th largest by planned enrollment of the 44 interventional ones that give a count, is the only one that started in 2023, is one of 16 in phase 3, and was the 44th registered.

Malaria

1,187 studies on the registry are indexed under Malaria; 80 are open to participants now.

Browse Malaria studies →

Open to participants now

2 of the 46 studies testing amodiaquine in Malaria are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About amodiaquine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 51 Malaria studies recruiting now, 15 (29%) set no upper age limit and 33 (65%) stop at 75 or younger; 37 take children under 18; 31 take healthy volunteers.

This study: 5 Years to 15 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing amodiaquine in Malaria, or all of them as a file.
02

Study summary

This will be an open label cluster randomized study with two active intervention and one control arm. A cluster will be defined as a selected village. One district implementing seasonal malaria chemoprevention (SMC) will be selected, and six villages will be randomly selected in this district. These six villages will be randomly allocated to each of the three study arms; 1) Arm 1 will receive IPTsc with sulphadoxine-pyrimethamine plus amodiaquine (SPAQ); and 2) Arm 2 will receive dihydroartemisinin-piperaquine (DP) plus Ivermectin (IVM), all given monthly during the transmission season and 3) Control Arm which will have standard malaria control measures including case management and vector control measures as applicable.

Read the detailed description

The overall objective of this study is to evaluate the efficacy, safety, implementation feasibility and cost-effectiveness of IPTsc with sulphadoxine-pyrimethamine plus amodiaquine (SPAQ) and dihydroartemisinin-piperaquine (DP) plus Ivermectin (IVM) for malaria prevention in this population.

Specific Objectives include the following.

  1. To evaluate the impact of IPTsc with SPAQ and DP plus IVM administered monthly during the transmission season on malaria burden 3. To understand the feasibility of and identify the most socially acceptable and sustainable way of achieving and maintaining high coverage of IPTsc with SPAQ and DP plus IVM 4. To determine the immunological and molecular epidemiological changes that occur in a nested population following IPTsc 5. To determine the cost and cost-effectiveness of these IPTsc approaches compared to existing standard malaria control interventions.

This will be an open label cluster randomized study with two active intervention and one control arm. A cluster will be defined as a selected village. One SMC implementing district will be selected, 6 villages will be randomly selected and allocated to each of the three study arms; 1) Arm 1 to receive IPTsc with SPAQ; and 2) Arm 2 to receive DP and IVM, all given monthly during the transmission season and 3) Control Arm standard malaria control measures including case management and vector control measures as applicable. This will result in a total of 18 clusters (villages) with 6 randomized to either of the three study arms. All children meeting eligibility criteria will be eligible to participate and to receive the IPTsc interventions. These criteria will include residence in the selected villages, willingness of parent/guardian to provide written informed consent and written assent by children, no known allergy to or contraindication to study medication, no history of cardiac conditions or long QT syndrome and no current use of medications known to prolong QT interval. Participants will receive the study drugs over one transmission season, monthly for five months. DP will be available as tablets of 320/40mg and 160/20mg piperaquine/dihydroartemisinin per tablet. Administration of a full course of DP will be done as per manufacturer's guidelines once daily for 3 days and according to body weight. DP will be taken orally with water and without food. IVM will be available as tablets of 3mg or 6mg strength. It will be given at 300-400μg/kg/day over 3 days (to the nearest whole tablet). IVM will also be taken on an empty stomach with water. The three-day SPAQ treatment course will consist of a co-blistered pack of dispersible tablets of sulfadoxine-pyrimethamine (SP) given on day 1 plus dispersible tablets of amodiaquine (AQ) which will be given once a day for 3 days. SPAQ will be dosed based on the child's age. The full 3-day course of all IPTsc medications will be administered each month under directly observed therapy (DOT). The control/standard of care arm will continue with the standard malaria control interventions provided by the malaria programme, including case management and long-lasting insecticidal nets (LLINs).

Study follow-up evaluations will be done using a system of passive case detection (PCD) established in the selected villages with the existing health facilities and community health workers and one cross sectional survey during the peak of the transmission season to determine prevalence of clinical malaria and malaria parasite prevalence. Sample size for this cross-sectional survey will be determined assuming study power of 80%, an alpha of 0.05 and an intra-cluster correlation coefficient of 0.01. A total of 50 children aged 5 to 15 years in each village/cluster (300 per study arms - total 900 children) will be required to detect a difference of at least a 10%-point reduction by either of the two IPTsc approaches in malaria prevalence from the 17% national estimate. Children will also be evaluated retrospectively for any illness, and prospectively for adverse events. In addition, a convenience sample of 20 participants in the \<5 years age group and 20 participants in the >15years age group will be randomly selected from each village/cluster (240 per study arm, total 720 participants) for enrollment into the cross sectional study to assess malaria prevalence in these age groups not receiving IPTsc as a measure of the potential impact of IPTsc on the general population malaria burden. These participants will be household contacts of children in the 5 - 15-year age group. The investigators will also conduct a process evaluation alongside the main clinical trial to track the standard malaria control interventions including quality of case management practices including availability of diagnostics and antimalarial drug stock levels and LLIN/IRS coverage and utilization rates throughout the study period in all study arms. The mosquitocidal effect of IVM will be assessed by determining mosquito densities in households of selected participants. Mosquitoes will be collected using CDC light traps in 4 randomly selected households in each arm, 12 in total, using a list randomly generated from the cluster database, monthly for 4 nights each month for the duration of transmission season. Sporozoïte rates and mosquito densities will be compared across the different study arms. As IVM also has a broad range of activity against numerous species of endo- and ectoparasites, the investigators will measure its impact on common ectoparasitic infections, including head lice and scabies. Reducing these infections would be an important auxiliary benefit of IVM. Dry blood spots will also be collected and stored for future immunological and molecular studies. The investigators will conduct a qualitative study to run alongside the main trial, to investigate acceptability of IPTsc and the potential feasibility of integrating this intervention into routine health services and school or community systems. This will be done through key informant interviews, in-depth interviews, focus group discussions and ethnographic observations in a randomly selected number of children, school administrators and relevant government departments. Although high acceptability of intermittent preventive treatment for other target groups has been previously reported, there's limited literature on acceptability in older children and adolescents. The investigators aim to identify best practices and challenges for integrating health programmes into existing programmes in Burkina Faso and other similar low resource settings, and to identify potential intervention methods and content to support future IPTsc scale-up. Post-intervention follow up will be done to assess for any rebound phenomenon using standard methodologies.

Laboratory Analysis: The following Lab evaluations will be done. Rapid Diagnostic Test (RDTs) will be performed according to the directions provided for the specific tests, using the blood transfer device and reagent provided by the manufacturer. Microcopy - thick blood smears will be stained with 2% Giemsa for 30 minutes and will be evaluated for the presence of parasitaemia (asexual forms only) and gametocytes. Parasite and gametocyte densities will be calculated from thick blood smears by counting the number of asexual parasites and gametocytes, respectively, per 200 leukocytes (or per 500, if the count is less than 10 parasites or gametocytes per 200 leukocytes), assuming a leukocyte count of 8,000/µl. A thick blood smear will be considered negative when the examination of 100 high power fields does not reveal asexual parasites or gametocytes. For quality control, all slides will be read by a second microscopist and a third reviewer will settle any discrepant. Molecular studies: samples will be analyzed with varATS qPCR using 5μL of extracted DNA per assay. The sensitivity of the assay will be approximately 0.02 parasites/μL of blood. Hemoglobin measurement will be done using a battery-operated portable HemoCue analyzer (HemoCue, Anglom, Sweden). Entomological monitoring - mosquitoes will be collected using CDC light traps in 3 randomly selected households in each arm, 12 in total, using a list randomly generated from the cluster database, monthly for the duration of one transmission season. Mosquito densities will be determined and Sporozoïtes will be identified using an enzyme linked immunosorbent assay (ELISA).

Markers of drug resistance - the investigators will determine the baseline prevalence's of SP, AQ, Dihydroartemisinin and Piperaquine resistance and any increase in resistance prevalence after one annual round of IPTsc as assessed via molecular markers in the population. Prevalence of the following mutations will be determined over time dhfr, dhps, pfcrt, pfmdr1, K13 and pfplm2. Serological Assays: immunological studies will be done at baseline and post intervention.

Malaria prevalence will be determined by technicians blinded to the treatment arms. Mosquitoes will be sampled using light-traps indoors, a sampling method that is not affected by operator bias. Mosquito analysis will be done in the laboratory, by individuals blinded to the origin of samples. Data on potential confounding factors (e.g., LLIN coverage) will be collected and used for adjustments in the analysis.

Qualitative research methods will assess potential sources of social desirability bias and potential factors for residual confounding.

Adverse Event Monitoring: adverse event monitoring will focus on severe adverse events (SAEs) and suspected unexpected adverse events (SUSARs). The prevalence and incidence of SAEs in children enrolled in the different intervention arms will be determined.

03

Conditions studied

  • Malaria

Browse trials for

04

Who can participate

Ages eligible
5 Years to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Resident in the study area and willing to remain there for the study duration
  • Age > or = 5 and \< 15 years
  • Willing to provide biological samples as requested during the study period
  • Provision of by parents/guardians
  • Provision of assent from children aged 12 to 15 years.

Exclusion criteria

Exclusion Criteria:

  • Any serious illness or medical situation that could interfere with follow-up
  • Inability to take study medication
  • History of known allergy or to study drugs
  • History of cardiac disorders or prolonged syndrome
  • Current use of drugs known to prolong QT interval
  • Participating in another research project.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
13,000 participants (estimated)

Study arms

  • Experimental
    Sulphadoxine-Pyrimethamine/Amodiaquine (SPAQ)

    SPAQ treatment will be given according to child's age. Dispersible tablets of sulphadoxine-pyrimethamine (SP) will be given on day 1 only. Dispersible tablets of amodiaquine (AQ) which will be given once a day for 3 days. The full 3-day course will be administered each month under directly observed therapy (DOT).

    Drug: Sulphadoxine-Pyrimethamine/Amodiaquine

  • Experimental
    Dihydroartemisinin/Piperaquine (DP) plus Ivermectin (IVM)

    DP will be available as tablets of 320/40mg and 160/20mg piperaquine/dihydroartemisinin per tablet. DP will be given once daily for 3 days and according to body weight. IVM will be given at 300-400μg/kg/day over 3 days (to the nearest whole tablet). IVM will also be taken on an empty stomach with water. Ivermectin will be available as 3 mg or 6 mg tablets to be administered at the doses of 300- 400μg/kg/day for 3 days (to the nearest whole tablet). IVM should also be taken with water on an empty stomach.

    Drug: Dihydroartemisinin/Piperaquine (DP) plus Ivermectin (IVM)

  • No intervention
    Control

    The control/standard of care arm will consist of the standard malaria control measures provided by the malaria programme, including case management and long-lasting insecticidal nets (LLINs).

Interventions

  • DrugSulphadoxine-Pyrimethamine/Amodiaquine

    Drug page: AmodiaquineStudies of AmodiaquineAmodiaquine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Co-blister packaging of sulfadoxine-pyrimethamine (SP) dispersible tablets administered on the first day and amodiaquine (AQ) dispersible tablets administered once daily for three days. The dose of SPAQ will be determined according to the child's age.

    Also known as: SPAQ

  • DrugDihydroartemisinin/Piperaquine (DP) plus Ivermectin (IVM)

    Drug pages: ArtenimolStudies of ArtenimolArtenimol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PiperaquineStudies of PiperaquinePiperaquine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · IvermectinStudies of IvermectinIvermectin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    DP will consist of tablets containing 320/40 mg and 160/20 mg piperaquine/dihydroartemisinin per tablet. A full course of DP should be administered in accordance with the manufacturer's instructions, once a day for 3 days, according to body weight. DP should be taken orally with water and without food. It will be given in association with Ivermectin. Ivermectin (IVM) will be available as 3 mg or 6 mg tablets to be administered at the doses of 300- 400μg/kg/day for 3 days (to the nearest whole tablet). IVM should also be taken with water on an empty stomach.

    Also known as: DP plus IVM

06

What researchers measure

Primary outcomes

  1. Prevalence of symptomatic malaria in children of the target age group by microscopy and molecular methods.

    prevalence of clinical malaria in the different study arms

    Time frame: 6 months

Secondary outcomes

  1. Prevalence of asymptomatic malaria

    prevalence of asymptomatic parasitemia in the different study arms

    Time frame: 6 months

  2. Prevalence of anemia

    prevalence of anemia in the different study arms

    Time frame: 6 months

  3. Prevalence of gametocytes determined by microscopy.

    prevalence of gametocytes in the different study arms

    Time frame: 6 months

  4. Prevalence of antimalarial drug resistance markers

    prevalence of antimalarial drug resistance markers in the different study arms

    Time frame: 6 months

  5. Acceptability of the two IPTsc approaches

    Acceptability of the two IPTsc approaches by the community.

    Time frame: 6 months

  6. Cost-effectiveness analysis of IPTsc with SPAQ and DP plus IVM from a provider perspective

    cost-effectiveness of the two IPTsc approaches

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for May 2024, 10 months after the start.

Of 44 non-industry phase 3 interventional studies under Malaria, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 34. This study's planned 10 months is below that.

Counting every sponsor, half of 50 studies reached it within 23 months; a quarter within 17 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2023
First posted
Jul 14, 2023
StartActual
Jul 15, 2023
Primary completionEst.
May 31, 2024
CompletionEst.
Dec 31, 2024
Last update
Nov 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05946642
Lead sponsor
Malaria Consortium
Responsible party
Sponsor
First posted
Jul 14, 2023
Start date
Jul 15, 2023
Primary completion
May 31, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Nov 22, 2023

Study contacts

Jane Achan, PhD
Contact
j.achan@malariaconsortium.org
+256770410183
Cheick Compaore, MSc
Contact
c.compaore@malariaconsortium.org
+22670168095
Jane Achan, PhD
principal investigator · Malaria Consortium

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Amodiaquine · Artenimol · Piperaquine · Ivermectin

Start the discussion